Table 6.
Top 25 canonical pathways significantly over-represented among overlapping genes associated with all traits in simplex and multiplex populations.
| Ingenuity canonical pathways | –log(p-value)* |
|---|---|
| Molecular Mechanisms of Cancer | 8.31 |
| Cell Cycle: G2/M DNA Damage Checkpoint Regulation | 6.85 |
| ATM Signaling | 6.64 |
| Estrogen Receptor Signaling | 6.37 |
| Senescence Pathway | 6.23 |
| Hypoxia Signaling in the Cardiovascular System | 6.16 |
| Cyclins and Cell Cycle Regulation | 6.16 |
| PI3K Signaling in B Lymphocytes | 6.08 |
| p70S6K Signaling | 5.55 |
| Cell Cycle Control of Chromosomal Replication | 5.24 |
| Protein Ubiquitination Pathway | 5.19 |
| Synaptogenesis Signaling Pathway | 5.03 |
| Regulation of eIF4 and p70S6K Signaling | 5.03 |
| Reelin Signaling in Neurons | 4.85 |
| Pyridoxal 5′-phosphate Salvage Pathway | 4.8 |
| ErbB4 Signaling | 4.68 |
| B Cell Receptor Signaling | 4.5 |
| NGF Signaling | 4.45 |
| Protein Kinase A Signaling | 4.15 |
| Opioid Signaling Pathway | 4.12 |
| Sumoylation Pathway | 4.11 |
| Systemic Lupus Erythematosus In B Cell Signaling Pathway | 4.02 |
| Natural Killer Cell Signaling | 4 |
| Ephrin Receptor Signaling | 4 |
| GM-CSF Signaling | 3.93 |
*
Negative logarithm of the Fisher Exact p-value which indicates the probability that the indicated pathway is not over-represented in the respective dataset of genes; a value of 1.3 is equivalent to a p-value of 0.05.
Boldface font indicates association with ASD.